←
Atanas G. Atanasov101,582 posts
Atanas G. Atanasov avatar

Atanas G. Atanasov

@_atanas_

Professor | Researcher | Editor-in-Chief | Scientific Consultant | Author | Educator #CRBIOTECH #ExplorDHT #DHPSP #INPST #PharmacologyPictureByPicture

◷ Joined December 2013▧ 492 Photos and videos
Atanas G. Atanasov avatar
⟳ Atanas G. Atanasov retweeted
Atanas G. Atanasov@_atanas_·Nov 14

Medicines can reshape gut microbes, while microbes can activate or inactivate drugs and alter toxicity, helping explain differences in treatment response. 🧵 1/7 “Integrating the gut microbiome and pharmacology.” 2024, Science Translational Medicine doi.org/10.1126/scitranslmed…

Dr. Sachse-Seeboth avatar
⟳ Atanas G. Atanasov retweeted
Dr. Sachse-Seeboth@DrSeeboth·Nov 16

It’s a world of its own. And it’s probably only through AI analysis that this complexity becomes accessible at all.

Medicines can reshape gut microbes, while microbes can activate or inactivate drugs and alter toxicity, helping explain differences in treatment response. 🧵 1/7 “Integrating the gut microbiome and pharmacology.” 2024, Science Translational Medicine doi.org/10.1126/scitranslmed…

Atanas G. Atanasov avatar
Atanas G. Atanasov@_atanas_·Nov 14

Randomized trials found no clear increase in Clostridioides difficile infection with proton pump inhibitors compared with placebo. 🧵 7/7 “Proton pump inhibitors are not associated with an increased risk of Clostridioides ...” 2025, Gut Microbes doi.org/10.1080/19490976.202…

Atanas G. Atanasov avatar
Atanas G. Atanasov@_atanas_·Nov 14

Gut microbes’ ability to inactivate mesalamine was linked to treatment failure in people with inflammatory bowel disease. 🧵 6/7 “Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease.” 2023, Nature Medicine nature.com/articles/s41591-0…

Atanas G. Atanasov avatar
Atanas G. Atanasov@_atanas_·Nov 14

Lower gut microbial diversity before treatment was linked to poorer antidepressant response in preliminary human studies. 🧵 5/7 “Psycho-Pharmacomicrobiomics: A Systematic Review and Meta-Analysis.” Published August 09, 2023, Biological Psychiatry doi.org/10.1016/j.biopsych.2…

Atanas G. Atanasov avatar
Atanas G. Atanasov@_atanas_·Nov 14

In type 2 diabetes, metformin use was linked to higher levels of several gut bacteria that produce short-chain fatty acids. 🧵 4/7 “The Microbial Regulation Spectrum of Metformin in Patients...” 2025, The Journal of Clinical Endocrinology & Metabolism doi.org/10.1210/clinem/dgaf2…

Atanas G. Atanasov avatar
Atanas G. Atanasov@_atanas_·Nov 14

Probiotics taken alongside antibiotics did not clearly preserve gut microbial diversity in randomized trials. 🧵 3/7 “Probiotic supplementation during antibiotic treatment is unjustified in maintaining the gut microbiome diversity: a systematic...” doi.org/10.1186/s12916-023-0…

Atanas G. Atanasov avatar
Atanas G. Atanasov@_atanas_·Nov 14

Antibiotic use four to eight years earlier was associated with lower gut microbial diversity in adults. 🧵 2/7 “Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals.” 2026, Nature Medicine nature.com/articles/s41591-0…

Dr. Peroxide ❄️ avatar
⟳ Atanas G. Atanasov retweeted
Dr. Peroxide ❄️@Drperoxide1·Nov 12

i pray that Bayer develops one that has to be approved for stroke prevention in patients with atrial fibrillation...thanks @_atanas_

Stroke prevention has a new target: factor XIa. The FDA approved asundexian with antiplatelet therapy after certain recent ischemic strokes or high-risk TIAs. In OCEANIC-STROKE, ischemic stroke risk fell 26% relative to placebo. fda.gov/news-events/press-an…

Post attachment
Kelly Anderson avatar
⟳ Atanas G. Atanasov retweeted
Kelly Anderson@kelly_archives·Nov 11

Targeting factor XIa represents an important development in stroke prevention. The focus on reducing recurrent ischemic events while managing bleeding risks marks a meaningful area of progress in cardiovascular research.

Stroke prevention has a new target: factor XIa. The FDA approved asundexian with antiplatelet therapy after certain recent ischemic strokes or high-risk TIAs. In OCEANIC-STROKE, ischemic stroke risk fell 26% relative to placebo. fda.gov/news-events/press-an…

Post attachment
Atanas G. Atanasov avatar
Atanas G. Atanasov@_atanas_·Nov 11

“Clinical Walking Speed, Free-Living Walking Cadence, and All-Cause Mortality.” Published October 23, 2026, JAMA Network Open. jamanetwork.com/journals/jam…